Skip to content

Dermacyd PH_DETINBACK Tangerine Mix (Lactic Acid) - Safety.

Safety Dermatological Evaluation: Vaginal Mucous Irritation - Product Tested: Dermacyd PH_DETINBACK Tangerine Mix (Lactic Acid).

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00783939
Enrollment
31
Registered
2008-11-03
Start date
2008-09-30
Completion date
Unknown
Last updated
2009-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hygiene

Brief summary

The purpose of this study is to prove the safety in normal conditions of useof the product Dermacyd PH\_DETINBACK Tangerine Mix (Lactic Acid).

Interventions

Lactic Acid (Dermacyd PH\_DETINBACK Tangerine Mix)

Sponsors

Sanofi
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
10 Years to 20 Years
Healthy volunteers
Yes

Inclusion criteria

* Age between 10 and 20 years old; * Integral skin test in the region; * Use of cosmetic product of the same category; * Willingness in following the study procedures and to be present in the clinic at the days and scheduled time;

Exclusion criteria

* Lactation or gestational risk or gestation; * Use of Anti-inflammatory, immunosuppression or antihistaminic drugs; * Atopic antecedent or allergic to cosmetic product; * Active cutaneous disease in the evaluation area; * Diseases which cause immunology decrease, such as diabetes and HIV; * Endocrinal pathologies; * Intense solar exposure 15 days before the evaluation; * Treatment until four months before the selection; The above information is not intended to contain all considerations relevant to a patient¿s potential participation in a clinical trial.

Design outcomes

Primary

MeasureTime frame
The absence of irritation and the good acceptability will be evaluated using one specific scale which describes the intensity of the reaction.From the treatment start to the end of the study

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026